SCHEMBL3376192

SCHEMBL3376192

CCOC(=O)c1cncc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2-n2cnc(Cl)c2Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.42
P2RY12 Q9H244 3/20 0.40
EGFR P00533 2/20 0.40
ERBB2 P04626 1/20 0.40
PAK1 Q13153 1/20 0.40
STK17A Q9UEE5 2/20 0.38
SYK P43405 1/20 0.37
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
AXL P30530 1/20 0.36
CSNK2A1 P68400 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MEN1 O00255 1/20 0.36
THRB P10828 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
STK17B O94768 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377106 0.88 XDH (0.42) EGFRSTK17AABL1BCRCSNK2A1
SCHEMBL3448560 0.88 FGFR1 (0.42) FGFR1P2RY12EGFRERBB2PAK1
SCHEMBL3448523 0.86 P2RY12 (0.43) FGFR1P2RY12EGFRERBB2PAK1
SCHEMBL3435889 0.86 FGFR1 (0.44) FGFR1P2RY12EGFRERBB2PAK1
SCHEMBL3451837 0.86 FGFR1 (0.42) FGFR1P2RY12EGFRERBB2PAK1
SCHEMBL3448621 0.86 P2RY12 (0.48) FGFR1P2RY12EGFRERBB2PAK1
SCHEMBL3449488 0.86 P2RY12 (0.48) FGFR1P2RY12EGFRERBB2PAK1
SCHEMBL13311563 0.85 NPC1 (0.45) FGFR1P2RY12EGFRERBB2PAK1
SCHEMBL3449393 0.85 EGFR (0.44) FGFR1P2RY12EGFRERBB2PAK1
SCHEMBL3448014 0.85 P2RY12 (0.47) FGFR1P2RY12EGFRERBB2PAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD FGFR1 3917/4885P2RY12 2175/4885EGFR 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.